2016-2017 Influenza Season

Please Note: CDC’s Advisory Committee on Immunization Practices (ACIP) voted in favor of an interim recommendation that live attenuated influenza vaccine (LAIV), also known as the “nasal spray” flu vaccine, should not be used during the 2016-2017 flu season. ACIP continues to recommend annual flu vaccination, with either the inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) for everyone 6 months and older. The ACIP vote follows data showing poor or relatively lower effectiveness of LAIV from 2013 through 2016. For more information, see the CDC Media Statement and Medscape Article

2016-2017 Early Vaccination Estimates:

  • Flu vaccination coverage as of early November 2016 was 39.8%, similar to coverage at the same time last flu season (39.7%) See full report at CDC.
  • As of early November 2016, flu vaccination coverage among pregnant women before and during pregnancy was 46.6%, approximately 6 percentage points higher compared with 2015–16 early-season vaccination coverage (40.2%). See full report at CDC.

2016-17 Flu Vaccine Effectiveness Interim Estimates:

During the period of November 28, 2016–February 4, 2017 overall vaccine effectiveness (VE) against influenza A and influenza B virus infection associated with medically attended ARI was 48%. Most influenza infections were caused by A (H3N2) viruses. VE was estimated to be 43% against illness caused by influenza A (H3N2) virus and 73% against influenza B virus. These interim VE estimates indicate that influenza vaccination reduced the risk for outpatient medical visits by almost half. Read the full MMWR Report.

Update on Influenza Activity in the U.S.:

Influenza activity in the United States began to increase in mid-December, remained elevated through February 4, 2017, and is expected to continue for several more weeks. To date, influenza A (H3N2) viruses have predominated overall, but influenza A (H1N1)pdm09 and influenza B viruses have also been identified.

2016-2017 Influenza Vaccination Recommendations:

Prevention and Control of Seasonal Influenza with Vaccines. Recommendations of the Advisory Committee on Immunization Practices — United States, 2016–17 Influenza Season. MMWR, August 26, 2016

Visit ACOG's Influenza Season Newsletter for monthly updates on then Influenza season!

Pregnant Women:
Pregnant women are at particularly high risk of severe illness and complications from influenza disease. Learn more at the Flu & Pregnancy page.'

ACOG Flu & Pregnancy Resources

The 2016-2017 Influenza Vaccine:

On March 4, 2016, the Food and Drug Administration's Vaccines and Related Biologics Advisory Committee (VRBPAC) endorsed the WHO-recommended vaccine viruses for use in all U.S. seasonal flu vaccines for the 2016-2017 flu season. It was recommended that trivalent vaccines for use in the 2016-2017 influenza season (Northern Hemisphere winter) contain the following:

  • an A/California/7/2009 (H1N1)pdm09-like virus;
  • an A/Hong Kong/4801/2014 (H3N2)-like virus;
  • a B/Brisbane/60/2008-like virus (B/Victoria lineage).

It was recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus (B/Yamagata lineage).

Vaccination Coverage during 2015-2016 Season:

Influenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine. Davlin SL, Blanton L, Kniss K, et al. Influenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 2016;65:567–575. DOI: http://dx.doi.org/10.15585/mmwr.mm6522a3

flu shot in pregnancy

Flu vaccination: a growing trend among pregnant women

This website is supported by an independent educational grant from Merck and an educational grant from Sanofi Pasteur U.S. 
ACOG does not allow companies to influence its programs, publications, or advocacy positions.